Insights

Strategic Collaborations MeiraGTx has recently entered into a strategic collaboration with Hologen AI, receiving significant upfront payment and forming a joint venture. This partnership aims to expedite Phase 3 clinical development of AAV-GAD for Parkinson's disease, presenting a potential sales opportunity for related treatments.

Regulatory Designation The FDA granted MeiraGTx Regenerative Medicine Advanced Therapy (RMAT) designation for AAV-GAD in treating Parkinson's disease. This designation allows for accelerated approval routes and frequent interactions with the FDA, setting the stage for potential sales growth and market positioning.

Gene Therapy Market Expansion MeiraGTx's focus on expanding genetic medicine applications beyond traditional areas like the eye and CNS opens up new markets and customer segments. With technology advancements and efficacy data supporting treatment in common diseases, there is a potential for broader sales outreach and revenue growth.

Global Market Potential Being part of the global gene therapy market, MeiraGTx stands to capitalize on the projected growth of segments such as cone rod dystrophy. With an emphasis on gene therapies, personalized medicine, and clinical trials, opportunities for international sales expansion are expected.

Promising Technology Platforms MeiraGTx's technology platforms focusing on precise gene regulation and cell therapy present innovative solutions for addressing unmet medical needs. As these technologies undergo clinical validation and gain regulatory approvals, sales opportunities in emerging therapeutic areas are likely to arise.

MeiraGTx Tech Stack

MeiraGTx uses 8 technology products and services including WordPress, NetSuite, Shopify, and more. Explore MeiraGTx's tech stack below.

  • WordPress
    Content Management System
  • NetSuite
    E-commerce
  • Shopify
    E-commerce
  • Nagios
    IT Infrastructure & Operations Management
  • Windows Server 2012
    Operating Systems
  • FedEx
    Transportation And Fleet Management
  • Minitab
    Visualisation Software
  • Adobe Fonts
    Web Fonts

Media & News

MeiraGTx's Email Address Formats

MeiraGTx uses at least 1 format(s):
MeiraGTx Email FormatsExamplePercentage
First.Last@meiragtx.comJohn.Doe@meiragtx.com
81%
First@meiragtx.comJohn@meiragtx.com
17%
First.L@meiragtx.comJohn.D@meiragtx.com
1%
FL@meiragtx.comJD@meiragtx.com
1%

Frequently Asked Questions

Where is MeiraGTx's headquarters located?

Minus sign iconPlus sign icon
MeiraGTx's main headquarters is located at 92 Brittania Walk, London/New York, N17NQ, GB. The company has employees across 3 continents, including EuropeNorth AmericaAsia.

What is MeiraGTx's phone number?

Minus sign iconPlus sign icon
You can contact MeiraGTx's main corporate office by phone at . For more prospecting data, LeadIQ has access to up-to-date and accurate contact information within our platform. Find, capture, and sync contact data to your CRM and sales tools in one click.

What is MeiraGTx's stock symbol?

Minus sign iconPlus sign icon
MeiraGTx is a publicly traded company; the company's stock symbol is MGTX.

What is MeiraGTx's official website and social media links?

Minus sign iconPlus sign icon
MeiraGTx's official website is meiragtx.com and has social profiles on LinkedInCrunchbase.

How much revenue does MeiraGTx generate?

Minus sign iconPlus sign icon
As of July 2025, MeiraGTx's annual revenue reached $35M.

What is MeiraGTx's SIC code NAICS code?

Minus sign iconPlus sign icon
MeiraGTx's SIC code is 8733 - Noncommercial Research Organizations NAICS code is 541714 - Research and Development in Biotechnology (except Nanobiotechnology).

How many employees does MeiraGTx have currently?

Minus sign iconPlus sign icon
As of July 2025, MeiraGTx has approximately 390 employees across 3 continents, including EuropeNorth AmericaAsia. Key team members include Chief Medical Officer: R. Z.Chief Operating Officer: R. G.Vice President Regulatory Affairs: A. M.. Explore MeiraGTx's employee directory with LeadIQ.

What industry does MeiraGTx belong to?

Minus sign iconPlus sign icon
MeiraGTx operates in the Biotechnology Research industry.

What technology does MeiraGTx use?

Minus sign iconPlus sign icon
MeiraGTx's tech stack includes WordPressNetSuiteShopifyNagiosWindows Server 2012FedExMinitabAdobe Fonts.

What is MeiraGTx's email format?

Minus sign iconPlus sign icon
MeiraGTx's email format typically follows the pattern of . Find more MeiraGTx email formats with LeadIQ.

How much funding has MeiraGTx raised to date?

Minus sign iconPlus sign icon
As of July 2025, MeiraGTx has raised $50M in funding. The last funding round occurred on Aug 12, 2024 for $50M.

When was MeiraGTx founded?

Minus sign iconPlus sign icon
MeiraGTx was founded in 2015.
MeiraGTx

MeiraGTx

Biotechnology ResearchUnited Kingdom201-500 Employees

MeiraGTx (Nasdaq: MGTX) is a vertically integrated, clinical-stage genetic medicine company with a broad pipeline of late-stage clinical programs supported by end-to-end manufacturing capabilities. MeiraGTx has an internally developed manufacturing platform process, internal plasmid production for GMP, two GMP viral vector production facilities as well as an in-house Quality Control hub for stability and release, all fit for IND through commercial supply. MeiraGTx has core capabilities in viral vector design and optimization and a potentially transformative riboswitch gene regulation platform technology that allows for the precise, dose-responsive control of gene expression by oral small molecules. MeiraGTx is focusing the riboswitch platform on delivery of metabolic peptides including GLP-1, GIP, Glucagon and PYY using oral small molecules, as well as cell therapy for oncology and autoimmune diseases. Although initially focusing on the eye, central nervous system, and salivary gland, MeiraGTx has developed the technology to apply genetic medicine to more common diseases, increasing efficacy, addressing novel targets, and expanding access in some of the largest disease areas where the unmet need remains great.

Section iconCompany Overview

Headquarters
92 Brittania Walk, London/New York, N17NQ, GB
Phone number
SIC Code
8733 - Noncommercial Research Organizations
Stock Symbol
MGTX
NAICS Code
541714 - Research and Development in Biotechnology (except Nanobiotechnology)
Founded
2015
Employees
201-500

Section iconFunding & Financials

  • $50M

    MeiraGTx has raised a total of $50M of funding over 5 rounds. Their latest funding round was raised on Aug 12, 2024 in the amount of $50M.

  • $10M$50M

    MeiraGTx's revenue is in the range of $10M$50M

Section iconFunding & Financials

  • $50M

    MeiraGTx has raised a total of $50M of funding over 5 rounds. Their latest funding round was raised on Aug 12, 2024 in the amount of $50M.

  • $10M$50M

    MeiraGTx's revenue is in the range of $10M$50M

Ready to create more pipeline?

Get a demo and discover why thousands of SDR and Sales teams trust
LeadIQ to help them build pipeline confidently.

© LeadIQ, Inc. All rights reserved.